Published time: 20 March 2020
Authors: Zeynep TIRMIKÇIOĞLU
Keywords: COVID-19, pregnancy, drug, teratogen
Coronaviruses include some of the agents that produce the common cold and some viruses that produce more severe respiratory syndromes. There have been case reports of normal and abnormal pregnancy outcomes after infection with Coronaviruses. Malformations have not been described. A new respiratory tract infection caused by coronaviruses was identified in 2019 and called COVID- 19. The virus causing COVID-19 has been named 2019- nCoV. There is no specific antiviral treatment for COVID-19. Oseltamivir and hydroxychloroquine have been used in the treatment of COVID- 19. In patients with pneumonia, azithromycin has also been used in combination with antiviral treatment. Lopinavir/ ritonavir can be used as second-line treatment for patients not responding to oseltamivir and hydroxychloroquine therapy. As yet, there is no evidence that pregnant women who get COVID-19 are more at risk of serious complications than any other healthy individuals. Clinicians normally hesitate in treating pregnant women by fear of causing damage to both the mother and baby. Meanwhile, many pregnant women think the treatment may be harmful to the baby. Drugs used for COVID-19 should be accurately evaluated for teratogenic risks. This paper presents a literature review regarding pregnancy outcomes after the use of therapeutic agents selected in COVID-19 treatment. After evaluation possible teratogenic effects, symptomatic prengnant patients with COVID-19 can also be treated with drugs used for other adult patients. There is a need for large-scale epidemiological studies in which the course of the infection during pregnancy and the effects of the drugs used on pregnancy and the fetus will be evaluated.
COVID-19 Enfeksiyonu Olan Gebelerde İlaç Kullanımı